SREBF1 and fatty liver disease: Although the exact role of PERK in hepatic steatosis is still not completely understood, a recent report also suggests that antipsychotic drugs (APDs)-induced activation of PERK-p-eIF2α signaling pathway increases intracellular lipid accumulation through activation of SREBP-1c and SREBP-2 in hepatocytes (Lauressergues et al., 2012).